nimotuzumab
Phase 3- Indications
- Head and neck cancer, Glioma, Non-small cell lung cancer, Pancreatic cancer
Company intelligence / Profile preview
CIMYM BioSciences
Ontario, Canadalinkedin.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
CIMYM BioSciences developed anti-EGFR monoclonal antibodies for oncology indications; their principal drug assets were ultimately discontinued, with no marketed products or ongoing clinical studies[1][3].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
CIMAB S.A. (Centro de Inmunología Molecular, Cuba, 20% JV partner)Gilead Sciences, Inc. (originator for mAbs assets; not a strategic partner but provided asset)
Beyond the preview
Go deeper on CIMYM BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIMYM BioSciences.